研報掘金丨民生證券:恆瑞醫藥管線蓄勢待發,維持“推薦”評級
民生證券研報指出,恆瑞醫藥(600276.SH)24年實現歸母淨利潤63.37億元,同比+47.28%;實現扣非歸母淨利潤61.78億元,同比+49.18%。業績增長超預期,經營效率持續提升。展望未來,公司管線蓄勢待發,公司預計2025年至2027年將分別有11項、13項、23項新產品/新適應症獲批。此外,公司持續深化全球佈局,目前正在推進超20項海外臨牀試驗,2024年公司4款ADC藥物獲得美國FDA的快速通道認定,3款首仿產品在美國獲批上市。維持“推薦”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.